MedCity News November 26, 2024
Frank Vinluan

Amgen’s experimental obesity drug, MariTide, led to an average 20% reduction in weight in a Phase 2 clinical trial. While investors hoped for greater weight loss, some analysts say less burdensome monthly dosing of MariTide could make it competitive against weekly injectable weight drugs Zepbound and Wegovy.

Highly anticipated Phase 2 data for Amgen’s obesity drug show that on average, participants lost about 20% of their weight after one year of treatment, results that put the experimental medicine in the ballpark of blockbuster Eli Lilly product Zepbound.

Zepbound and Novo Nordisk’s Wegovy are both administered as weekly injections. Amgen’s drug, maridebart cafraglutide, or MariTide, was tested with doses administered monthly or even less frequently. In the consumer-driven obesity drug market,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Pharma / Biotech
Related Articles:
FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions
Bariatric Surgeons Being Put Out of Work by GLP-1 Drugs
The CMS NHE 2023 Report: An Incomplete Picture at a Pivotal Time
Gene Therapy Shows Long-Term Vision Benefits in Rare Eye Disease
A Biologist Explains The ‘Weird’ Habits Of People Who Live To 100+ Years Old

Share This Article